{"id":24138,"date":"2022-04-29T11:10:01","date_gmt":"2022-04-29T11:10:01","guid":{"rendered":"https:\/\/celonpharma.com\/?p=24138"},"modified":"2025-04-04T12:53:11","modified_gmt":"2025-04-04T12:53:11","slug":"current-report-no-10-2022-submission-of-an-application-to-the-food-and-drug-administration-fda-for-the-granting-the-breakthrough-designation-to-falkieri-celons-esketamine-dpi-in-treat","status":"publish","type":"post","link":"https:\/\/celon.group\/en\/2022\/04\/29\/current-report-no-10-2022-submission-of-an-application-to-the-food-and-drug-administration-fda-for-the-granting-the-breakthrough-designation-to-falkieri-celons-esketamine-dpi-in-treat\/","title":{"rendered":"Current report No. 10\/2022 \u2013 Submission of an application to the Food and Drug Administration (FDA) for the granting the Breakthrough Designation to Falkieri (Celon&#8217;s esketamine DPI) in treatment-resistant bipolar depression therapy"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">The Management Board of Celon Pharma S.A. (the \u201cCompany\u201d) hereby informs that on April 20, 2022 an application was submitted to the Food and Drug Administration (FDA) for the granting of the Breakthrough Designation to Falkieri (Celon&#8217;s esketamine DPI) in treatment-resistant bipolar depression therapy.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This application is supported by results of pre-clinical and clinical trials, in particular the treatment-resistant bipolar depression phase II trial, in which the esketamine DPI developed by the Company has demonstrated an exceptional clinical benefit.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The Company anticipates that the American regulator&#8217;s decision in that matter will be announced within approx. 60 days.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">For Falkieri (Celon\u2019s esketamine DPI), the procedure for granting the Breakthrough Designation would offer a number of advantages; regulatory, clinical and administrative facilitation for the applicant. It can significantly accelerate the market admission of this therapy in the US.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In the opinion of the Company&#8217;s Management Board, assignment of the aforementioned status significantly increases the commercialization value of the project, and simultaneously minimizes the regulatory risk for the potential partner.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Management Board of Celon Pharma S.A. (the \u201cCompany\u201d) hereby informs that on April 20, 2022 an application was submitted to the Food and Drug Administration (FDA) for the granting of the Breakthrough Designation to Falkieri (Celon&#8217;s esketamine DPI) in treatment-resistant bipolar depression therapy. This application is supported by results of pre-clinical and clinical trials,<a class=\"excerpt-read-more float-right\" href=\"https:\/\/celon.group\/en\/2022\/04\/29\/current-report-no-10-2022-submission-of-an-application-to-the-food-and-drug-administration-fda-for-the-granting-the-breakthrough-designation-to-falkieri-celons-esketamine-dpi-in-treat\/\" title=\"ReadCurrent report No. 10\/2022 \u2013 Submission of an application to the Food and Drug Administration (FDA) for the granting the Breakthrough Designation to Falkieri (Celon&#8217;s esketamine DPI) in treatment-resistant bipolar depression therapy\">Read more &raquo;<\/a><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[26],"tags":[],"class_list":["post-24138","post","type-post","status-publish","format-standard","hentry","category-general-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.8.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Current report No. 10\/2022 \u2013 Submission of an application to the Food and Drug Administration (FDA) for the granting the Breakthrough Designation to Falkieri (Celon&#039;s esketamine DPI) in treatment-resistant bipolar depression therapy - CelonGROUP<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"http:\/\/celon.group\/en\/2022\/04\/29\/current-report-no-10-2022-submission-of-an-application-to-the-food-and-drug-administration-fda-for-the-granting-the-breakthrough-designation-to-falkieri-celons-esketamine-dpi-in-treat\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Current report No. 10\/2022 \u2013 Submission of an application to the Food and Drug Administration (FDA) for the granting the Breakthrough Designation to Falkieri (Celon&#039;s esketamine DPI) in treatment-resistant bipolar depression therapy - CelonGROUP\" \/>\n<meta property=\"og:description\" content=\"The Management Board of Celon Pharma S.A. (the \u201cCompany\u201d) hereby informs that on April 20, 2022 an application was submitted to the Food and Drug Administration (FDA) for the granting of the Breakthrough Designation to Falkieri (Celon&#8217;s esketamine DPI) in treatment-resistant bipolar depression therapy. This application is supported by results of pre-clinical and clinical trials,Read more &raquo;\" \/>\n<meta property=\"og:url\" content=\"http:\/\/celon.group\/en\/2022\/04\/29\/current-report-no-10-2022-submission-of-an-application-to-the-food-and-drug-administration-fda-for-the-granting-the-breakthrough-designation-to-falkieri-celons-esketamine-dpi-in-treat\/\" \/>\n<meta property=\"og:site_name\" content=\"CelonGROUP\" \/>\n<meta property=\"article:published_time\" content=\"2022-04-29T11:10:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-04T12:53:11+00:00\" \/>\n<meta name=\"author\" content=\"Ma\u0142gorzata Siewierska\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ma\u0142gorzata Siewierska\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"http:\/\/celon.group\/en\/2022\/04\/29\/current-report-no-10-2022-submission-of-an-application-to-the-food-and-drug-administration-fda-for-the-granting-the-breakthrough-designation-to-falkieri-celons-esketamine-dpi-in-treat\/\",\"url\":\"http:\/\/celon.group\/en\/2022\/04\/29\/current-report-no-10-2022-submission-of-an-application-to-the-food-and-drug-administration-fda-for-the-granting-the-breakthrough-designation-to-falkieri-celons-esketamine-dpi-in-treat\/\",\"name\":\"Current report No. 10\/2022 \u2013 Submission of an application to the Food and Drug Administration (FDA) for the granting the Breakthrough Designation to Falkieri (Celon's esketamine DPI) in treatment-resistant bipolar depression therapy - CelonGROUP\",\"isPartOf\":{\"@id\":\"https:\/\/celon.group\/en\/#website\"},\"datePublished\":\"2022-04-29T11:10:01+00:00\",\"dateModified\":\"2025-04-04T12:53:11+00:00\",\"author\":{\"@id\":\"https:\/\/celon.group\/en\/#\/schema\/person\/e0ffc863fc928f3fd9bd67757492badf\"},\"breadcrumb\":{\"@id\":\"http:\/\/celon.group\/en\/2022\/04\/29\/current-report-no-10-2022-submission-of-an-application-to-the-food-and-drug-administration-fda-for-the-granting-the-breakthrough-designation-to-falkieri-celons-esketamine-dpi-in-treat\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"http:\/\/celon.group\/en\/2022\/04\/29\/current-report-no-10-2022-submission-of-an-application-to-the-food-and-drug-administration-fda-for-the-granting-the-breakthrough-designation-to-falkieri-celons-esketamine-dpi-in-treat\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"http:\/\/celon.group\/en\/2022\/04\/29\/current-report-no-10-2022-submission-of-an-application-to-the-food-and-drug-administration-fda-for-the-granting-the-breakthrough-designation-to-falkieri-celons-esketamine-dpi-in-treat\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/celon.group\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Current report No. 10\/2022 \u2013 Submission of an application to the Food and Drug Administration (FDA) for the granting the Breakthrough Designation to Falkieri (Celon&#8217;s esketamine DPI) in treatment-resistant bipolar depression therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/celon.group\/en\/#website\",\"url\":\"https:\/\/celon.group\/en\/\",\"name\":\"CelonGROUP\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/celon.group\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/celon.group\/en\/#\/schema\/person\/e0ffc863fc928f3fd9bd67757492badf\",\"name\":\"Ma\u0142gorzata Siewierska\",\"url\":\"https:\/\/celon.group\/en\/author\/malgorzata-siewierska\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Current report No. 10\/2022 \u2013 Submission of an application to the Food and Drug Administration (FDA) for the granting the Breakthrough Designation to Falkieri (Celon's esketamine DPI) in treatment-resistant bipolar depression therapy - CelonGROUP","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"http:\/\/celon.group\/en\/2022\/04\/29\/current-report-no-10-2022-submission-of-an-application-to-the-food-and-drug-administration-fda-for-the-granting-the-breakthrough-designation-to-falkieri-celons-esketamine-dpi-in-treat\/","og_locale":"en_US","og_type":"article","og_title":"Current report No. 10\/2022 \u2013 Submission of an application to the Food and Drug Administration (FDA) for the granting the Breakthrough Designation to Falkieri (Celon's esketamine DPI) in treatment-resistant bipolar depression therapy - CelonGROUP","og_description":"The Management Board of Celon Pharma S.A. (the \u201cCompany\u201d) hereby informs that on April 20, 2022 an application was submitted to the Food and Drug Administration (FDA) for the granting of the Breakthrough Designation to Falkieri (Celon&#8217;s esketamine DPI) in treatment-resistant bipolar depression therapy. This application is supported by results of pre-clinical and clinical trials,Read more &raquo;","og_url":"http:\/\/celon.group\/en\/2022\/04\/29\/current-report-no-10-2022-submission-of-an-application-to-the-food-and-drug-administration-fda-for-the-granting-the-breakthrough-designation-to-falkieri-celons-esketamine-dpi-in-treat\/","og_site_name":"CelonGROUP","article_published_time":"2022-04-29T11:10:01+00:00","article_modified_time":"2025-04-04T12:53:11+00:00","author":"Ma\u0142gorzata Siewierska","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Ma\u0142gorzata Siewierska","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"http:\/\/celon.group\/en\/2022\/04\/29\/current-report-no-10-2022-submission-of-an-application-to-the-food-and-drug-administration-fda-for-the-granting-the-breakthrough-designation-to-falkieri-celons-esketamine-dpi-in-treat\/","url":"http:\/\/celon.group\/en\/2022\/04\/29\/current-report-no-10-2022-submission-of-an-application-to-the-food-and-drug-administration-fda-for-the-granting-the-breakthrough-designation-to-falkieri-celons-esketamine-dpi-in-treat\/","name":"Current report No. 10\/2022 \u2013 Submission of an application to the Food and Drug Administration (FDA) for the granting the Breakthrough Designation to Falkieri (Celon's esketamine DPI) in treatment-resistant bipolar depression therapy - CelonGROUP","isPartOf":{"@id":"https:\/\/celon.group\/en\/#website"},"datePublished":"2022-04-29T11:10:01+00:00","dateModified":"2025-04-04T12:53:11+00:00","author":{"@id":"https:\/\/celon.group\/en\/#\/schema\/person\/e0ffc863fc928f3fd9bd67757492badf"},"breadcrumb":{"@id":"http:\/\/celon.group\/en\/2022\/04\/29\/current-report-no-10-2022-submission-of-an-application-to-the-food-and-drug-administration-fda-for-the-granting-the-breakthrough-designation-to-falkieri-celons-esketamine-dpi-in-treat\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["http:\/\/celon.group\/en\/2022\/04\/29\/current-report-no-10-2022-submission-of-an-application-to-the-food-and-drug-administration-fda-for-the-granting-the-breakthrough-designation-to-falkieri-celons-esketamine-dpi-in-treat\/"]}]},{"@type":"BreadcrumbList","@id":"http:\/\/celon.group\/en\/2022\/04\/29\/current-report-no-10-2022-submission-of-an-application-to-the-food-and-drug-administration-fda-for-the-granting-the-breakthrough-designation-to-falkieri-celons-esketamine-dpi-in-treat\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/celon.group\/en\/"},{"@type":"ListItem","position":2,"name":"Current report No. 10\/2022 \u2013 Submission of an application to the Food and Drug Administration (FDA) for the granting the Breakthrough Designation to Falkieri (Celon&#8217;s esketamine DPI) in treatment-resistant bipolar depression therapy"}]},{"@type":"WebSite","@id":"https:\/\/celon.group\/en\/#website","url":"https:\/\/celon.group\/en\/","name":"CelonGROUP","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/celon.group\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/celon.group\/en\/#\/schema\/person\/e0ffc863fc928f3fd9bd67757492badf","name":"Ma\u0142gorzata Siewierska","url":"https:\/\/celon.group\/en\/author\/malgorzata-siewierska\/"}]}},"_links":{"self":[{"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/posts\/24138","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/comments?post=24138"}],"version-history":[{"count":1,"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/posts\/24138\/revisions"}],"predecessor-version":[{"id":40202,"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/posts\/24138\/revisions\/40202"}],"wp:attachment":[{"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/media?parent=24138"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/categories?post=24138"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/tags?post=24138"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}